Neurogene Inc.

NGNE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $103.8M $136.6M $148.2M $82.0M $142.5M $192.6M $143.1M $76.9M
Accounts Receivable
Inventory
Total Current Assets $271.8M $315.9M $200.3M $84.7M $144.0M $194.5M $143.6M $77.2M
Property, Plant & Equipment $12.8M $15.4M $17.2M $20.1M $3.6M $2.1M $400.0K
Goodwill
Intangible Assets (Excl. Goodwill) $0 $128.0K $347.0K $567.0K
Total Assets $288.6M $335.7M $222.6M $109.3M $163.3M $210.5M $147.0M $77.6M
Liabilities
Accounts Payable $2.0M $1.3M $2.6M $625.0K $526.0K $1.3M $1.6M $702.0K
Total Current Liabilities $16.4M $15.2M $23.0M $6.7M $8.6M $7.9M $4.7M $4.6M
Long-Term Debt
Total Liabilities $23.7M $25.4M $36.5M $10.6M $20.4M $19.3M $5.3M $4.9M
Stockholders' Equity
Retained Earnings $-352.6M $-262.3M $-187.2M $-150.8M $-393.5M $-332.8M $-299.5M $-230.1M
Total Stockholders' Equity $264.9M $310.4M $186.0M $-145.7M $-91.9M $191.2M $141.7M $72.7M
← Newer Page 1 of 2 Older →